🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

60 results for “Vanda” Clear

  1. 20 mg VEC-162

    Vanda Pharmaceuticals Netherlands B.V.

    Insomnia

    phase 3 small molecule completed

    1 trial

  2. 750 mg Imsidolimab

    Vanda Pharmaceuticals Netherlands B.V.

    Generalized Pustular Psoriasis

    phase 3 small molecule completed

    1 trial

  3. Double-blind 200 mg imsidolimab

    Vanda Pharmaceuticals Netherlands B.V.

    Generalized Pustular Psoriasis

    phase 3 small molecule terminated

    1 trial

  4. Iloperidone

    Vanda Pharmaceuticals Netherlands B.V.

    Bipolar I Disorder

    phase 3 small molecule completed

    2 trials

  5. Milsaperidone

    Vanda Pharmaceuticals Netherlands B.V.

    Major Depressive Disorder (MDD)

    phase 3 small molecule active

    1 trial

  6. Placebo will be provided in size and appearance identical to those containing milsaperidone and will be administered orally., Milsaperidone, Milsaperidone, Milsaperidone

    Vanda Pharmaceuticals Netherlands B.V.

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  7. Ponesimod

    Vanda Pharmaceuticals Netherlands B.V.

    Moderate-to-severe Chronic Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  8. Tasimelteon

    Vanda Pharmaceuticals Netherlands B.V.

    Jet Lag Type Insomnia

    phase 3 small molecule completed

    1 trial

  9. Tasimelteon

    Vanda Pharmaceuticals Netherlands B.V.

    Sleep Wake Disorders

    phase 3 small molecule active

    2 trials

  10. Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension

    Vanda Pharmaceuticals Netherlands B.V.

    Autism Spectrum Disorder

    phase 3 small molecule active

    1 trial

  11. Tasimelteon Oral Suspension

    Vanda Pharmaceuticals Netherlands B.V.

    Insomnia Disorder

    phase 3 small molecule active

    1 trial

  12. Tradipitant

    Vanda Pharmaceuticals Netherlands B.V.

    Nausea and Vomiting

    phase 3 small molecule active

    1 trial

  13. Tradipitant

    Vanda Pharmaceuticals Netherlands B.V.

    Motion Sickness

    phase 3 small molecule active

    4 trials

  14. Tradipitant

    Vanda Pharmaceuticals Netherlands B.V.

    Idiopathic Gastroparesis

    phase 3 small molecule active

    2 trials

  15. Tradipitant

    Vanda Pharmaceuticals Netherlands B.V.

    Atopic Dermatitis

    phase 3 small molecule completed

    3 trials

  16. Tradipitant

    Vanda Pharmaceuticals Netherlands B.V.

    Coronavirus Infection

    phase 3 small molecule active

    1 trial

  17. VEC-162 20 mg

    Vanda Pharmaceuticals Netherlands B.V.

    Primary Insomnia

    phase 3 small molecule completed

    1 trial

  18. VQW-765

    Vanda Pharmaceuticals Netherlands B.V.

    Social Anxiety Disorder (SAD)

    phase 3 small molecule active

    1 trial

  19. tasimelteon

    Vanda Pharmaceuticals Netherlands B.V.

    Non 24 Hour Sleep Wake Disorder

    phase 3 small molecule active

    4 trials

  20. tasimelteon

    Vanda Pharmaceuticals Netherlands B.V.

    Smith-Magenis Syndrome

    phase 3 small molecule completed

    1 trial

  21. tasimelteon

    Vanda Pharmaceuticals Netherlands B.V.

    Major Depressive Disorder

    phase 3 small molecule completed

    1 trial

  22. Iloperidone

    Vanda Pharmaceuticals Netherlands B.V.

    Parkinson Disease Psychosis

    phase 2 small molecule terminated

    1 trial

  23. Iloperidone crystalline formulation

    Vanda Pharmaceuticals Netherlands B.V.

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  24. Imsidolimab

    Vanda Pharmaceuticals Netherlands B.V.

    Hidradenitis Suppurativa

    phase 2 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources